ES2180571T3 - Antagonistas de ligando para el tratamiento de cancer de mama. - Google Patents
Antagonistas de ligando para el tratamiento de cancer de mama.Info
- Publication number
- ES2180571T3 ES2180571T3 ES94909578T ES94909578T ES2180571T3 ES 2180571 T3 ES2180571 T3 ES 2180571T3 ES 94909578 T ES94909578 T ES 94909578T ES 94909578 T ES94909578 T ES 94909578T ES 2180571 T3 ES2180571 T3 ES 2180571T3
- Authority
- ES
- Spain
- Prior art keywords
- receptor
- ligands
- growth
- hormone
- novel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 abstract 6
- 239000000122 growth hormone Substances 0.000 abstract 4
- 108020003175 receptors Proteins 0.000 abstract 4
- 239000000556 agonist Substances 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 108010003044 Placental Lactogen Proteins 0.000 abstract 1
- 239000000381 Placental Lactogen Substances 0.000 abstract 1
- 102100024819 Prolactin Human genes 0.000 abstract 1
- 108010057464 Prolactin Proteins 0.000 abstract 1
- 102100038803 Somatotropin Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000002942 anti-growth Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 108091008039 hormone receptors Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940097325 prolactin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
HEMOS DESCUBIERTO QUE LAS HORMONAS DE CRECIMIENTO FORMAN COMPLEJOS TERNARIOS CON SUS RECEPTORES EN DONDE EL LUGAR 1 DE LA HORMONA SE UNE PRIMERO A UNA MOLECULA DEL RECEPTOR Y A CONTINUACION LA HORMONA DEL LUGAR 2 SE UNE A OTRA MOLECULA DEL RECEPTOR, CON LO QUE SE PRODUCE UN COMPLEJO 1:2. CREEMOS QUE ESTE FENOMENO ES COMPARTIDO POR OTROS LIGANDOS QUE TIENEN UNA ESTRUCTURA CONFORMACIONAL SIMILAR. LOS ENSAYOS BASADOS EN ESTE FENOMENO SON UTILES PARA IDENTIFICAR AGONISTAS Y ANTAGONISTAS DE LIGANDOS. SE HAN IDENTIFICADO ESTRUCTURALMENTE LOS LUGARES 1 Y 2 PARA FACILITAR LA GENERACION DE VARIANTES DE SECUENCIAS DE AMINOACIDOS DE LIGANDOS QUE FORMAN COMPLEJOS TERNARIOS. SE PRESENTAN NUEVOS VARIANTES DE HORMONAS DE CRECIMIENTO, LACTOGENO PLACENTARIO DE PROLACTINA Y OTROS LIGANDOS RELACIONADOS. COMO RESULTADO DE NUESTROS ESTUDIOS CON EL COMPLEJO TERNARIO HEMOS DETERMINADO QUE ALGUNOS ANTICUERPOS SELECCIONADOS AL RECEPTOR DE ESTOS LIGANDOS SON CAPACES DE ACTUAR A MODO DE AGONISTAS O ANTAGONISTAS DE LIGANDOS. SE DESCRIBEN NUEVAS HORMONAS DE CRECIMIENTO Y NUEVOS USOS DE LOS ANTICUERPOS DE RECEPTORES DE HORMONAS ANTICRECIMIENTO. TAMBIEN SE DESCRIBEN LOS METODOS PARA INHIBIR EL CRECIMIENTO DE CELULAS QUE PROVOCAN EL CANCER DE MAMA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2032793A | 1993-02-19 | 1993-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2180571T3 true ES2180571T3 (es) | 2003-02-16 |
Family
ID=21798003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94909578T Expired - Lifetime ES2180571T3 (es) | 1993-02-19 | 1994-02-09 | Antagonistas de ligando para el tratamiento de cancer de mama. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0684835B1 (es) |
| JP (1) | JP3983280B2 (es) |
| AT (1) | ATE220916T1 (es) |
| CA (1) | CA2154163C (es) |
| DE (1) | DE69431041T2 (es) |
| DK (1) | DK0684835T3 (es) |
| ES (1) | ES2180571T3 (es) |
| HK (1) | HK1010990A1 (es) |
| PT (1) | PT684835E (es) |
| WO (1) | WO1994019004A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| PT1079851E (pt) * | 1998-05-12 | 2007-10-08 | Greenville Hospital System | ''utilização de agentes anti-prolactina para tratar cancro'' |
| JP4593754B2 (ja) * | 2000-10-13 | 2010-12-08 | 一般財団法人 化学物質評価研究機構 | 化学物質の５０％阻害濃度決定方法 |
| FR2833011B1 (fr) * | 2001-12-04 | 2004-10-29 | Univ Claude Bernard Lyon | Nouvelle proteine a activite inhibitrice de l'il-6 |
| EP2336779B1 (en) | 2004-02-19 | 2013-07-31 | Yale University | Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992019736A1 (en) * | 1991-05-01 | 1992-11-12 | Ohio University | Growth hormone antagonists |
| DE69231467T2 (de) * | 1991-05-10 | 2001-01-25 | Genentech Inc | Auswählen von agonisten und antagonisten von liganden |
-
1994
- 1994-02-09 WO PCT/US1994/001444 patent/WO1994019004A1/en active IP Right Grant
- 1994-02-09 PT PT94909578T patent/PT684835E/pt unknown
- 1994-02-09 DK DK94909578T patent/DK0684835T3/da active
- 1994-02-09 CA CA002154163A patent/CA2154163C/en not_active Expired - Fee Related
- 1994-02-09 DE DE69431041T patent/DE69431041T2/de not_active Expired - Lifetime
- 1994-02-09 EP EP94909578A patent/EP0684835B1/en not_active Expired - Lifetime
- 1994-02-09 JP JP51844694A patent/JP3983280B2/ja not_active Expired - Lifetime
- 1994-02-09 ES ES94909578T patent/ES2180571T3/es not_active Expired - Lifetime
- 1994-02-09 AT AT94909578T patent/ATE220916T1/de not_active IP Right Cessation
-
1998
- 1998-11-18 HK HK98112097A patent/HK1010990A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU685434B2 (en) | 1998-01-22 |
| AU6237894A (en) | 1994-09-14 |
| EP0684835B1 (en) | 2002-07-24 |
| DK0684835T3 (da) | 2002-11-11 |
| PT684835E (pt) | 2002-12-31 |
| EP0684835A1 (en) | 1995-12-06 |
| DE69431041D1 (de) | 2002-08-29 |
| WO1994019004A1 (en) | 1994-09-01 |
| HK1010990A1 (en) | 1999-07-02 |
| CA2154163C (en) | 2009-12-01 |
| JPH08506591A (ja) | 1996-07-16 |
| ATE220916T1 (de) | 2002-08-15 |
| DE69431041T2 (de) | 2003-02-06 |
| JP3983280B2 (ja) | 2007-09-26 |
| CA2154163A1 (en) | 1994-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE196548T1 (de) | Auswählen von agonisten und antagonisten von liganden | |
| LESNIAK et al. | Human growth hormone radioreceptor assay using cultured human lymphocytes | |
| ATE184019T1 (de) | Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen | |
| EA200301117A1 (ru) | Антитела против vla-1 | |
| DE2902400A1 (de) | Verbesserter, spezifischer doppelrezeptor-bindetest fuer einen probenliganden | |
| KR850004594A (ko) | 펩타이드의 제조방법 | |
| ES8607564A1 (es) | Un metodo para determinar la presencia de un determinante antigenico de interleuquina-2-en una muestra. | |
| ATE183195T1 (de) | Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren | |
| Mardiney Jr et al. | Ultrastructural localization of the third and fourth components of complement on complement-cell complexes. | |
| Perkins | A study of the amino-acid complexes formed by metals of Group II of the periodic classification | |
| ES2180571T3 (es) | Antagonistas de ligando para el tratamiento de cancer de mama. | |
| CA1177825A (en) | Polypeptide analgesics | |
| GB2098730A (en) | Immunolocalisation | |
| TW272197B (es) | ||
| Moyle et al. | Detection of conformational changes in human chorionic gonadotropin upon binding to rat gonadal receptors. | |
| Baran et al. | Characterization of the soluble murine IL-2R and estimation of its affinity for IL-2. | |
| Møller et al. | Fc-mediated immune precipitation. III. Visualization by electron microscopy. | |
| DE3411472A1 (de) | Verfahren zum bestimmen der anwesenheit von insulin, antiinsulinantikoerper, verfahren zur bestimmung des menschlichen insulinniveaus und verfahren zur bestimmung von humaninsulin | |
| Mansour et al. | Multiple opioid receptor subtypes in the pituitary-adrenal axis: a cross-species study. | |
| Hong et al. | Univalence of half-molecules of rabbit antibody | |
| ATE188248T1 (de) | Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen auf liganden, die an proteine der cytoadhesin-superfamilie binden | |
| Podder et al. | 2-(1-Naphthylmethyl)-2-imidazoline hydrochloride (naphazoline hydrochloride), C14H15N2+. Cl−, an α-adrenergic agonist | |
| Araki | Serological Diagnosis of the Heart Disease (V): II Anti Cor Phosphatide Reaction (ACPR) | |
| LÜDDENS et al. | Characterization of the porcine ACTH receptor with the aid of a monoclonal antibody | |
| DE2646223A1 (de) | Neue verbesserte organische verbindungen |